The Rabbit Monoclonal anti-IL18BP antibody (Clone 31I00) (ABIN7881287) specifically detects IL18BP in WB and IHC.
The antibody is reactive with Human and Rat samples.
IL18BP
Reactivity: Human
ELISA, IHC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Optimal dilution of the IL18BP antibody should be determined by the researcher.
Restrictions
For Research Use only
Format
Liquid
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Store the IL18BP antibody at -20oC.
Target
IL18BP
(Interleukin 18 Binding Protein (IL18BP))
Alternative Name
IL18BP
Background
IL18BP antibody detects interleukin 18 binding protein, encoded by the IL18BP gene. This secreted glycoprotein functions as a natural inhibitor of interleukin 18, a proinflammatory cytokine. Alternate names include IL18BPa, IL18BPb, and IL18BPc, reflecting the multiple isoforms generated by alternative splicing. IL18BP neutralizes IL18 by binding with high affinity, preventing its interaction with the IL18 receptor and subsequent activation of NF kappa B and interferon gamma pathways.
IL18BP antibody is widely applied in immunology, inflammation research, and translational medicine. By detecting IL18BP, researchers can investigate how immune regulation balances inflammatory cytokine activity. Overexpression of IL18BP provides protection from excessive inflammation, while deficiency or altered expression contributes to autoimmune disorders and infectious disease susceptibility.
ELISA detects IL18BP in serum and culture supernatants, while western blotting identifies isoform expression. Immunohistochemistry maps IL18BP production in tissues undergoing immune activation. These methods make IL18BP antibody useful for evaluating cytokine regulation in health and disease.
IL18BP has therapeutic potential as a biologic agent. Recombinant IL18BP has been developed to treat inflammatory diseases such as adult onset Still disease and hemophagocytic lymphohistiocytosis. By applying IL18BP antibody, researchers can monitor therapeutic levels and investigate how modulation of IL18 signaling influences disease outcomes.
IL18BP antibody from NSJ Bioreagents delivers dependable specificity for analyzing interleukin 18 binding protein. Its reliable performance across assays ensures accurate detection of this immune regulator.